Pharma

RegenxBio sues FDA over clinical hold

RegenxBio sues FDA over clinical hold

By Keith Croes | November 27, 2019

Days after the U.S. Food and Drug Administration placed a partial hold on RGX-314, RegenxBio (NASDAQ: RGNX) lead gene therapy agent, the company initially outlined…

Read More
Bausch, Clearside See Gains Post-Deal

Bausch, Clearside See Gains Post-Deal

By Steve Lenier | November 20, 2019

When it comes to the stock market, Bausch Health’s has been rising steadily, up 4.1% in the past month, and on November 13 hit a…

Read More
OIS INDEX Oyster Point

Oyster Point Pharma Goes Public

By Michelle Dalton | November 14, 2019

Oyster Point Pharma is now officially listed on the Nasdaq Global Market under “OYST.” Initial share pricing was $16; to date the stock’s high has…

Read More
Digging deep in the retina pipeline

Digging deep in the retina pipeline

By Rich Kirkner | November 13, 2019

While Novartis’ recently approved Beovu soaked up a lot of the buzz in the retina space at the American Academy of Ophthalmology, reports of early…

Read More
Ain’t Misbehaving

Ain’t Misbehaving

By Steve Lenier | October 23, 2019

What a difference a day (or so) makes. On Oct. 10, the day of the Ophthalmic Innovation Summit, Aerie Pharmaceuticals’ stock closed at $17.72. The…

Read More
OIS@ASRS at the Ritz-Carlton Chicago: An In-depth Look at the Retina Space

OIS@ASRS at the Ritz-Carlton Chicago: An In-depth Look at the Retina Space

By Keith Croes | July 17, 2019

CHICAGO – The extensive, intensive public and private investment in the retinal space will fill the day next Thursday, July 25, at the OIS@ASRS meeting,…

Read More
Ocular Therapeutix’s Strong Bounce Back

After Re-submitted NDA a Year Ago, Ocular Therapeutix Finds Its Path Forward

By Steve Lenier | June 19, 2019

In July 2018 Ocular Therapeutix re-submitted its New Drug Application for Dextenza to the Food and Drug Administration. At that time, Scott Corning, the company’s…

Read More
Novartis’ New Head of Ophthalmology Lays Out Lofty Goals Days Before Xiidra Deal

Novartis’ New Head of Ophthalmology Lays Out Lofty Goals Days Before Xiidra Deal

By Michelle Dalton | May 14, 2019

VANCOUVER – Novartis is one of the world’s largest ophthalmic pharmaceutical companies, with $4.6 billion in assets as part of the Medicines division, yet some…

Read More
Protocol V, LEAVO Among Retina Highlights at ARVO

Protocol V, LEAVO Among Retina Highlights at ARVO 2019

By Michelle Dalton | May 1, 2019

VANCOUVER – Leave it to ARVO 2019 – the Association for Research in Vision and Ophthalmology – to keep attendees waiting until mid-evening to hear…

Read More
Will Dexycu’s Cost Inhibit Its Use?

Will Dexycu’s Cost Inhibit Its Use?

By Steve Lenier | April 10, 2019

Eric Donnenfeld, MD, of Ophthalmic Consultants of Long Island, recently performed the first cataract surgery in the country using Dexycu (EyePoint Pharmaceuticals), administered as a…

Read More
Will a New Drug Using Cannabinoids Achieve a Breakthrough for Glaucoma?

Will a New Drug Using Cannabinoids Achieve a Breakthrough for Glaucoma?

By Heather Johnson | March 19, 2019

SAN FRANCISCO – Nemus Bioscience, a biopharmaceutical company based in Southern California, came to the Glaucoma 360 New Horizons Forum here in February to make…

Read More
Nicox Patiently Pursues Moves to Build Value

Nicox Patiently Pursues Moves to Build Value

By Steve Lenier | January 23, 2019

Nicox SA has taken several steps in the past few months to increase shareholder value. It has two product candidates headed toward Phase II trials,…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.